Organisations › Chemical

Rafa Laboratories

Jerusalem, IsraelFounded 1937Industry

Rafa Laboratories, based in Jerusalem, manufactures emergency medical countermeasures including a 2 mg atropine auto-injector, FDA-approved in July 2018, for poisoning by organophosphate nerve agents and some insecticides. It supplies the product to US government and NATO member states.

What it does

auto-injectorsmedical countermeasuresatropine auto-injector

Threats covered

nerve agentsorganophosphate poisoning
Categories

Profile

Rafa Laboratories is a Jerusalem pharmaceutical company founded in 1937 that manufactures atropine auto-injectors used to treat nerve agent and insecticide poisoning. According to its own history, it developed its first atropine auto-injector with the Israeli Ministry of Defense in 1990 and supplied it to the Israeli population during the Gulf War.

More profile

Its biodefense site presents a CBRN product line built around auto-injectors. In 2020 the FIMI private equity group bought control of the company at a valuation of about 700 million shekels, according to a financial newspaper, with the founding family keeping a minority stake.

Ownership

Controlled by FIMI Opportunity Funds since 2020; the founding family retained a minority stake

Parent: FIMI Opportunity Funds

Sources (5)
Not verified or not found
  • Contracts and customers beyond the Israeli Ministry of Defense: not found.
  • Current ownership percentages: not stated.
  • Recent developments: none found.
Questions

What does Rafa Laboratories do?

Rafa Laboratories, based in Jerusalem, manufactures emergency medical countermeasures including a 2 mg atropine auto-injector, FDA-approved in July 2018, for poisoning by organophosphate nerve agents and some insecticides. It supplies the product to US government and NATO member states.

Where is Rafa Laboratories based?

HQ (as found): Jerusalem. HQ country: IL.

Who owns Rafa Laboratories?

Controlled by FIMI Opportunity Funds since 2020; the founding family retained a minority stake. Parent: FIMI Opportunity Funds

Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction